Earnings · US stocks

Celldex Therapeutics, Inc. (CLDX) earnings

Celldex Therapeutics, Inc. published its quarterly report on 2026-11-05. The stock moved +8.42% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-05
Result
Bad / loss
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+5.66%—
3 days+8.42%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 3 of them. The stock rose in the 3 trading days after 5 of 8 reports (average +3.04%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-05-0.96+3.39%+8.42%——
2026-08-06-0.94+11.41%+6.67%-7.99%-7.09%
2026-05-07-1.18-4.22%-3.96%+0.27%-1.48%
2026-02-25-1.22-22.50%-2.66%+9.09%+11.00%
2025-11-10-1.01-13.16%+4.63%+17.25%+16.29%
2025-08-07-0.85-0.96%+12.21%+16.03%+11.06%
2025-05-08-0.81-9.09%+0.51%+4.46%-1.75%
2025-02-27-0.71+0.64%-1.53%-21.52%-11.18%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: CLDX

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.